View in EDS

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Saved in:
Bibliographic Details
Title: Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
Authors: Awasthi R; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ., Grupp SA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA., Waldron ER; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Yanik GA; Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI., Tam CS; Peter MacCallum Cancer Centre, Alfred Hospital and Monash University, Melbourne, VIC, Australia., Rives S; Leukemia and Lymphoma Department, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain., McGuirk JP; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Pulsipher MA; Intermountain Primary Children's Hospital Division of Hematology and Oncology, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT., Jaeger U; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital, Medical University of Vienna, Vienna, Austria., Myers GD; Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO., Borchmann P; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Stefanski HE; National Marrow Donor Program, Minneapolis, MN., Bishop MR; The David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Chakraborty A; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ., Masood A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Baruchel A; Hématologie-Immunologie Pédiatrique, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris and Université Paris Cité, Paris, France., Waller EK; Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA.
Source: Blood advances [Blood Adv] 2025 Sep 09; Vol. 9 (17), pp. 4405-4414.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40554413
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Awasthi+R%22">Awasthi R</searchLink>; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Grupp+SA%22">Grupp SA</searchLink>; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Waldron+ER%22">Waldron ER</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Yanik+GA%22">Yanik GA</searchLink>; Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI.<br /><searchLink fieldCode="AU" term="%22Tam+CS%22">Tam CS</searchLink>; Peter MacCallum Cancer Centre, Alfred Hospital and Monash University, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Rives+S%22">Rives S</searchLink>; Leukemia and Lymphoma Department, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22McGuirk+JP%22">McGuirk JP</searchLink>; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Pulsipher+MA%22">Pulsipher MA</searchLink>; Intermountain Primary Children's Hospital Division of Hematology and Oncology, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Jaeger+U%22">Jaeger U</searchLink>; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Myers+GD%22">Myers GD</searchLink>; Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO.<br /><searchLink fieldCode="AU" term="%22Borchmann+P%22">Borchmann P</searchLink>; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Schuster+SJ%22">Schuster SJ</searchLink>; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Stefanski+HE%22">Stefanski HE</searchLink>; National Marrow Donor Program, Minneapolis, MN.<br /><searchLink fieldCode="AU" term="%22Bishop+MR%22">Bishop MR</searchLink>; The David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Chakraborty+A%22">Chakraborty A</searchLink>; BioMedical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Masood+A%22">Masood A</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Baruchel+A%22">Baruchel A</searchLink>; Hématologie-Immunologie Pédiatrique, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris and Université Paris Cité, Paris, France.<br /><searchLink fieldCode="AU" term="%22Waller+EK%22">Waller EK</searchLink>; Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Sep 09; Vol. 9 (17), pp. 4405-4414.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40554413
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2024014995
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4405
    Titles:
      – TitleFull: Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Awasthi R
      – PersonEntity:
          Name:
            NameFull: Grupp SA
      – PersonEntity:
          Name:
            NameFull: Waldron ER
      – PersonEntity:
          Name:
            NameFull: Yanik GA
      – PersonEntity:
          Name:
            NameFull: Tam CS
      – PersonEntity:
          Name:
            NameFull: Rives S
      – PersonEntity:
          Name:
            NameFull: McGuirk JP
      – PersonEntity:
          Name:
            NameFull: Pulsipher MA
      – PersonEntity:
          Name:
            NameFull: Jaeger U
      – PersonEntity:
          Name:
            NameFull: Myers GD
      – PersonEntity:
          Name:
            NameFull: Borchmann P
      – PersonEntity:
          Name:
            NameFull: Schuster SJ
      – PersonEntity:
          Name:
            NameFull: Stefanski HE
      – PersonEntity:
          Name:
            NameFull: Bishop MR
      – PersonEntity:
          Name:
            NameFull: Chakraborty A
      – PersonEntity:
          Name:
            NameFull: Masood A
      – PersonEntity:
          Name:
            NameFull: Baruchel A
      – PersonEntity:
          Name:
            NameFull: Waller EK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 09
              Text: 2025 Sep 09
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 17
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1